Nasdaq GlobeNewswire

Genomatica brings its naturally sourced Brontide(TM) butylene glycol to Europe

Del

Azelis chosen to distribute; already confirming better personal care formulations

SAN DIEGO and ANTWERP, Belgium, March 20, 2018 (GLOBE NEWSWIRE) -- Genomatica, a widely-recognized technology leader for naturally sourced chemicals, and Azelis, a leading distributor of specialty chemicals, announced that Azelis is now the exclusive distributor for personal care applications of Genomatica's naturally sourced, award-winning Brontide(TM) butylene glycol in Europe. Azelis is already seeing widespread interest in Brontide from major brands and plans to support scores of major customers during Brontide's market introduction. See Brontide introduction video.

Photos accompanying this announcement are available at
http://www.globenewswire.com/NewsRoom/AttachmentNg/689e9f6d-b2ba-4977-ac51-3a74b9e6fba9

http://www.globenewswire.com/NewsRoom/AttachmentNg/7baf9c6b-8b96-4326-8049-a57d4c22a177

A naturally sourced, sustainable cosmetics ingredient; Brontide honored for innovation

Butylene glycol, a colorless organic alcohol, is commonly used in a wide range of personal care products to increase moisture retention (as a humectant), improve texture, and provide antimicrobial properties. Additionally, it is used to evenly disperse plant extracts, flavors and fragrances.

Genomatica produces Brontide biobased butylene glycol from natural, plant-based sugars using its safe and sustainable fermentation-based process technology. This innovative approach has high appeal in personal care applications where demand for natural ingredients is growing. Brontide has already been recognized by the mainstream chemical industry with the prestigious ICIS Innovation Award.

Azelis actively developing formulations; sees strong customer interest

Azelis, a leading global specialty chemicals distributor with over 40,000 customers in 40 countries will provide sales, technical and logistics support for personal care product makers in Europe that are looking for a natural alternative to petroleum-based butylene glycol.

Azelis has also been actively developing and testing multiple personal care product formulations using Genomatica's Brontide, including hydra gels, body sprays, and sunscreens. These have tested well for key formulation attributes such as scent, viscosity, pH and stability.

Azelis reports that demand for natural ingredients has multiplied across its customer base. "We're already seeing strong interest in Genomatica's Brontide butylene glycol," said Tony Craske, Market Segment Director EMEA for Personal Care, Azelis. "Brontide is a perfect example of the new and exciting technologies that we deliver to our personal care partners. This naturally sourced, sustainable high-quality ingredient makes it easy for formulators and brands to improve their products."

"Azelis knows how to highlight the value of a great ingredient and help their customers benefit from it," said Damien Perriman, Genomatica's Senior Vice President, Specialty Chemicals. "Together, we can help make lots of everyday products better for people and the planet."

Genomatica has been producing and shipping tons of Brontide to customers since mid-2017. For samples, companies developing personal care products in Europe should contact Azelis at Brontide.BG@azelis.com; all others should contact Genomatica at Brontide@genomatica.com.

About Azelis

Azelis is a leading distributor of speciality chemicals and food ingredients present in over 40 countries across the globe with around 1,800 employees. Our knowledgeable teams of industry, market and technical experts are each dedicated to a specific market within Life Sciences and Industrial Chemicals. We offer a lateral value chain of complementary products to over 40,000 customers, creating a turnover of €1.8 billion. In the US we operate under a number of renowned co-brands that cater to the various markets in the region.

Throughout our extensive network of 39 application laboratories, our award-winning technical staff help customers develop formulations. We combine a global reach with a local focus to offer a reliable, integrated service to local customers and attractive business opportunities to principals. And we believe in building and nurturing solid, honest and transparent relationships with our people and partners.

Creating value, growing together. www.azelis.com

About Genomatica

Genomatica is a widely-recognized leader in bioengineering. It develops biobased process technologies that enable a better way to produce widely-used chemicals, from alternative feedstocks, with better economics, sustainability and performance. Genomatica has earned widespread acclaim for its technology and commercialization achievements. Awards include the Kirkpatrick Award, for "the most noteworthy chemical engineering technology commercialized in the world" and the ICIS Innovation Award for its Brontide(TM) butylene glycol. To learn more, visit www.genomatica.com

For more information

For Azelis: Marina Kaptein, +32 3 613 0125, marina.kaptein@azelis.com
For Genomatica: Patti Bianchi, CG Life, +1.630.841.1771, pbianchi@cglife.com




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Genomatica via Globenewswire

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Bombardier Delivers First 90-seat Q400 Aircraft to SpiceJet21.9.2018 16:00Pressemelding

SpiceJet becomes the first airline to take advantage of the Q400 aircraft’s increased profit potential TORONTO, Sept. 21, 2018 (GLOBE NEWSWIRE) -- Bombardier Commercial Aircraft today announced the delivery of its first 90-seat Q400 aircraft. The aircraft was handed over to India’s SpiceJet Limited (“SpiceJet”) the launch operator for the extra-capacity, 90-seat aircraft. “We are excited to induct the 90-seat Q400 aircraft into our fleet,” said Ajay Singh, Chairman and Managing Director, SpiceJet. “The additional seats and performance improvements will result in substantial reduction in unit costs and also we will enable us to address our market needs in the regional space.” “The delivery of the first 90-seat Q400 aircraft showcases the commitment of Bombardier’s Q Series turboprop program to respond to customer requirements as they address traffic growth in regional markets,” said Todd Young, Head of the Q Series Aircraft Program, Bombardier Commercial Aircraft. “I thank and congratul

Service Providers Speed Deployment, Reduce Costs with Patton Cloud Edge Orchestration Service20.9.2018 22:16Pressemelding

Now, Telecom and UCaaS service providers can easily provision, manage, monitor, secure, alert, troubleshoot, analyze, and optimize services on the customer premise GAITHERSBURG, Md., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Patton Electronics—US-manufacturer of UC, cloud, and IoT-enabling solutions for carrier, enterprise, and industrial networks—has launched the new Patton Cloud service for carriers and service providers that deliver All-IP and hybrid voice-and-data services to business subscribers. Patton Cloud delivers a low-cost, easy-to-use, web-based edge-orchestration service that delivers a superior user experience. It offers remote touchless provisioning, monitoring, and troubleshooting—as well as security and alerting tools that reduce service turn-up costs, trouble tickets, and subscriber attrition. The Patton Cloud service offers quality-control mechanisms including pro-active monitoring and troubleshooting—combined with feature-license distribution pools for managing value-added

Inspirata Promotes Top Executives to Expanded Roles in Digital Pathology20.9.2018 21:12Pressemelding

Inspirata Founder and Executive Vice President, Mark Lloyd, is taking on an expanded role overseeing product management, and Inspirata Senior Vice President, Andrew Chomos, has been appointed to General Manager, Digital Pathology, overseeing the Center of Excellence in Pittsburgh along with all North America sales and customer support efforts. Tampa, FL, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Cancer informatics and digital pathology workflow solution provider Inspirata®, Inc. announced today that two of its executives have taken on expanded roles in the company. The two are Inspirata Executive Vice President and Founder, Mark Lloyd, and Senior Vice President and General Manager, Digital Pathology, Andrew Chomos. Dr. Lloyd has accepted the expansion of his role to include product management for Digital Pathology. He is former cancer researcher at both Lombardi Cancer and Moffitt Cancer Center and is Inspirata’s foremost subject matter expert and thought leader on digital pathology and image

Tetraphase Pharmaceuticals Announces Adoption of Commission Decision Granting Marketing Authorisation Approval in the European Union for XERAVA™ (eravacycline) for the Treatment of Complicated Intra-Abdominal Infections20.9.2018 19:08Pressemelding

– Broad Product Label for Treatment of Complicated Intra-Abdominal Infections – – Phased Commercial Launch Expected in the First Half of 2019 – WATERTOWN, Mass., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH), a biopharmaceutical company focused on developing and commercializing novel antibiotics to treat life-threatening multidrug-resistant (MDR) infections, today announced that the European Commission (EC) has adopted the Decision granting marketing authorisation for XERAVA (eravacycline) for injection for the treatment of complicated intra-abdominal infections (cIAI) in adults in the European Union. In clinical trials, XERAVA was well-tolerated and achieved high clinical cure rates in patients with cIAI, demonstrating statistical non-inferiority to two widely used comparators – ertapenem and meropenem. “The European approval of XERAVA, right after our recently announced FDA approval, marks our second significant regulatory approval within one month

UPDATE— Taconic Biosciences Becomes the First Animal Model Provider on General Services Administration Contract Schedule20.9.2018 18:07Pressemelding

RENSSELAER, N.Y., Sept. 20, 2018 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in providing genetically engineered rodent model solutions, announces a new relationship with Government Scientific Source (GSS). GSS is a leading dedicated distributor of laboratory equipment to federal, state, and local governments on contract with the GSA (General Services Administration). By having Taconic’s products available via GSS, they can now be accessed by all federal agencies, including but not limited to the National Institutes of Health and the Department of Defense. Taconic is the only animal model provider affiliated with GSS and the only animal model provider available on GSA Contract. “An important component of providing customers with the best animal model solutions is access to key resources. Through this exciting new relationship with GSS, Taconic can now easily connect with scientists doing some of the most valuable research in the world and provide them with high quality sol

Digital Transformation is Not a One-Off — It’s About the Digital Journey20.9.2018 17:44Pressemelding

SoftServe study confirms four digital journey states with 71 percent of enterprises reporting early stages of adoption AUSTIN, Texas, Sept. 20, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital authority and consulting company, today released the results of its market research study that examines how enterprises are responding to the digital economy. The research found that 71 percent of the respondents in the United States and the European Union are in the early stages—Reveal and Transform—of four unique states across the Enterprise Digital Journey. For an in-depth analysis and the full results, read The Enterprise Digital Journey white paper. With fierce competition in today’s global landscape, leveraging cutting-edge technology and deploying new business models is not a one-off pursuit, but rather a continuous process of iteration and refinement. Companies should stop referring to Digital Transformation and instead plan for a continuous Digital Journey. “The term Digital Transfo

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom